Overview
Phase I Chinese PK
Status:
Completed
Completed
Trial end date:
2007-11-01
2007-11-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
An open, phase 1 to assess the PK of rising doses of ZD6474 when administered daily in Chinese patients with advanced solid malignant tumors.Phase:
Phase 1Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Genzyme, a Sanofi Company
Criteria
Inclusion Criteria:- histological and/or cytological confirmation of a malignant solid tumor
- refractory to standard therapies or for which no appropriate therapies exist
- WHO performance status 0-2
Exclusion Criteria:
- patients with brain tumors or symptomatic cerebral metastases
- systemic anticancer therapy within the last 4 weeks